

Paxman publishes newsletter on increasing investor interest for the company in the United States

Today, Paxman publishes the March issue of its newsletter aimed at shareholders, investors and other interested parties.

This issue highlights that Paxman's CEO Richard Paxman conducted several investor meetings in the United States to follow up on increasing investor interest for the company since the engagement of US based Arrowhead Business and Investment Decisions towards the end of 2022. Visit Arrowhead's dedicated Paxman Page to learn more about their analysis of the company, and the latest Equity Research Report can be found here.

The newsletter also includes information on that CEO Richard Paxman participated at an export event in Leeds held by the Department for Business and Trade to share knowledge and experience of Paxman's export journey to the United States, that the prominent US breast cancer physician Alberto Montero visited the Paxman Scalp Cooling Research Centre, successful certifications of distributors from Saudi Arabia, Romania and the Czech Republic, as well as on a number of orders to the United States, the UK and several international markets.

To read the full newsletter, follow this link:

https://bit.ly/paxmar23en

This is the final issue of Paxman's monthly investor newsletter. Going forward, stakeholders are recommended to follow the news flow directly on Paxman's website and the company's social media channels.

Contacts

Richard Paxman, CEO Tel: +44 7968 020641 Email: richard@paxmanscalpcooling.com www.paxman.se



About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 4,400 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN's scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company's Certified Adviser.

Attachments

Paxman publishes newsletter on increasing investor interest for the company in the United States